首页> 外文期刊>Infection >Linezolid-related pancytopenia in organ-transplant patients: report of two cases.
【24h】

Linezolid-related pancytopenia in organ-transplant patients: report of two cases.

机译:器官移植患者中利奈唑胺相关的全血细胞减少:2例报告。

获取原文
获取原文并翻译 | 示例
       

摘要

Linezolid is a recent oral antibiotic used in drug-resistant Gram-positive cocci infection. We herein report on the first two cases of linezolid-related pancytopenia in organ-transplant patients. Both patients had methicillineresistant Staphylococcus aureus infections. Pancytopenia, i.e. aregenerative anemia, neutropenia and thrombopenia, developed 3 weeks and 5 weeks after initiating linezolid therapy at a conventional dosage (600 mg bid). There were no other confounding causes of pancytopenia, which resolved promptly after withdrawing linezolid. Because of the potential hazards of pancytopenia in immunosuppressed organ-transplant patients, we advocate the cautious use of linezolid for transplant patients.
机译:利奈唑胺是最近用于抗药性革兰氏阳性球菌感染的口服抗生素。我们在此报告了器官移植患者中与利奈唑胺相关的全血细胞减少症的前两个病例。两名患者均具有耐甲氧西林的金黄色葡萄球菌感染。全血细胞减少症,即再生性贫血,中性粒细胞减少和血小板减少症,在以常规剂量(600 mg bid)开始利奈唑胺治疗后3周和5周发展。没有其他引起全血细胞减少的混杂原因,撤除利奈唑胺后迅速解决。由于免疫抑制的器官移植患者存在全血细胞减少症的潜在危险,因此我们建议在移植患者中谨慎使用利奈唑胺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号